【摘要】 gp41是HIV-1表面的一种包膜糖蛋白,介导了病毒膜和宿主细胞膜间的融合,在HIV-1的侵染过程中起关键作用。以gp41为靶点的HIV-1融合抑制剂是近年来抗HIV-1药物研究的热点。其中多肽类T-20药物在美国的成功上市为该类药物的研发工作带来了希望。本文就gp41的结构、作用机制和目前抗HIV-1融合抑制剂的研究进展进行了综述。更多还原

【Abstract】 Process of fusion of the HIV-1 with target cell membranes is an important step for HIV-1 infection.HIV-1 gp41 has become an attractive therapeutic target because it is the major protein component on the viral surface and mediates the key stages of viral entry.T-20(enfuvirtide),the first fusion inhibitor targeting HIV-1 gp41,has been successfully approved by FDA,and has ushered in a new chapter in the development of anti-HIV-1 therapeutics.This review summarizes the structure and mechanism of gp41,and the advancement of some fusion inhibitors these years.更多还原